| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ac87b204a7bc3150bda0d77fde2766c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec927927f2c2ae2c6a265b2c9ee673ce |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3621
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-525 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-14 |
| filingDate |
2009-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bfb867f33f756af6ffad40a6db2dc8f |
| publicationDate |
2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8501918-B2 |
| titleOfInvention |
Immobilized tumor necrosis factor-α muteins for enhancing immune response in mammals |
| abstract |
The present invention provides a method for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The method involves the removal of immune system inhibitors such as soluble TNF receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent. The removal of immune system inhibitors is accomplished by contacting biological fluids of a mammal with one or more binding partner(s) such as TNFα muteins capable of binding to and, thus, depleting the targeted immune system inhibitor(s) from the biological fluids. Particularly useful in the invention is an absorbent matrix composed of an inert, biocompatible substrate joined covalently to a binding partner, such as a TNFα mutein, capable of specifically binding to a targeted immune system inhibitor such as soluble TNF receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458236-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11224858-B1 |
| priorityDate |
2005-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |